Long-term tolerance of zidovudine treatment was retrospectively analysed in 97 patients with AIDS or AIDS-related complex. After one year of treatment 68% and after two years 87% of the patients had had at least one dose adjustment during their course of therapy.
Myelotoxicity was the most common cause (58% of all cases) of dose reductions and therapy interruptions (dose adjustments). At the time ofthe first dose adjustment 33 patients (34%) were suffering from anaemia (Hb < 6-0 g/dl), 20 patients (21%) from leukopenia (leukocytes < 1-5 x 10'), and 10 patients (10%) from thrombocytopenia (thrombocytes <75 x 10'). Fifty-six patients (57%) needed one or more blood transfusions during therapy. The median time from the start of therapy to the time ofthe first dose adjustment was 14 (range: ) weeks in patients who had a first dose adjustment because of anaemia without coexisting leukopenia or thrombocytopenia, and 37 (range: 6-85) weeks in patients who had a first dose adjustment because of leukopenia without co-existing anaemia or thrombocytopenia (p = 0-01). Peripheral blood CD4 positive lymphocyte counts <100/mm3, anaemia, and CDC classification IV-C1 at the start of treatment were associated with a need for an early dose modification or blood transfusion rather than the need for dose modification per se. Zidovudine treatment is associated with toxicities which limit its use.' In this respect bone marrow toxicity is most important. Anaemia, which can be macrocytic or normocytic is frequently found. After prolonged therapy, leukopenia (primarily attributable to neutropenia) and thrombocytopenia can occur. Bone marrow toxicity has been observed more frequently in patients with pretreatment anaemia, neutropenia, low numbers of peripheral blood CD4 positive lymphocytes or a low serum level of vitamin B12.69 Other toxicities seen in patients receiving zidovudine are headaches, nausea, malaise and myalgia.6' Myopathy can occur after prolonged treatment. 1012 15 In a recent study from France, during a treatment period of 31 weeks only 21% of patients with AIDS tolerated full-dose treatment without a dose reduction or therapy interruption.9 We performed a retrospective analysis with a longer follow-up period (up to 147 weeks) in order to determine the long-term tolerance of zidovudine in our patient population with AIDS and ARC. In 59 patients (70%) with dose adjustments concomitant potentially myelotoxic therapy was used, in most cases given in low dosages as secondary prophylactic therapy for opportunistic infections.
Methods
In 35 patients (42% of all patients with dose adjustments) no haematological abnormalities were seen. Dose adjustments in these cases commonly were interruptions of therapy because of subjective side effects such as nausea, or because of terminal disease. In only one case clinically evident myopathy, which was histologically proven, was reason for the discontinuation of therapy.
CDC stage of disease, haemoglobin level, and peripheral blood CD4 positive lymphocyte counts at the start of therapy were tested as predictive factors for toxicity. Table 2 shows that CDC classification IV-C1, haemoglobin <6-0 mmol/l, and CD4 positive lymphocyte counts < 100/mm3 were associated with the occurrence of an early dose modification and/or an early blood transfusion. There were no significant differences between groups in the number of patients that eventually developed toxicity.
Discussion
This analysis shows that only a minority of patients with severe symptomatic HIV-1 -related disease can tolerate full-dose zidovudine regimens for prolonged periods. After one year of treatment 68% and after two years 87% of the patients had had at least one dose adjustment during their course of therapy (Kaplan-Meier-curve). These findings are comparable with the rate found in the extended follow-up from the original American phase II study.'5 24 weeks. This period did not appear to be significantly different from the time to the occurrence of anaemia or from the time to the occurrence of leukopenia. As reported in earlier studies,69 peripheral blood CD4 positive lymphocyte counts below or equal to 100/mm3, anaemia, and CDC classification IV-C1 at the start of treatment were associated with poor tolerance of full dose zidovudine treatment. Our study, with a longer follow-up, shows that these markers predict a need for an early dose modification or blood transfusion rather than the need for dose modification per se.
Concomitant potential myelotoxic medicine was often used (in 70% of the patients). In most cases it was given as low dose prophylactic therapy for opportunistic infections, which makes it unlikely that this played a major role in the observed toxicity.-Although dose reductions were followed by subsequent therapy interruptions in a majority of cases, zidovudine treatment could often be continued for an extended period thereafter; 40% of the patients were still on the drug a half year after a first reduction.
Haematological toxicity was the most common reason for a dose modification. In 35 patients (42% of all dose adjustments) however, zidovudine was stopped for other reasons, such as nonhaematological side effects or terminal disease. Myopathy has been reported to occur in an increasing number of patients on long-term zidovudine therapy. '"2" In this study only one case of histologically proven myopathy was seen, although 54 patients did receive zidovudine for more than a year.
Thus, the majority of patients with AIDS or ARC who are treated with a high dose of zidovudine, at this moment the sole antiretroviral drug which is licensed, cannot be maintained on these regimens, most commonly due to the development of haematological toxicity. Up until now the established zidovudine starting dose in many countries has been 1000-1500 mg per day. Treatment with lower daily doses of zidovudine may lead to reduced toxicity, while maintaining efficacy.`' It is, however, as yet unknown what influence such low-dose regimens will have on the rate at which viral drug resistance develops.`v"" Treatment with cytokines, such as granulocyte-and granulocyte-macrophage colony stimulating factors and erythropoietin, may be another promising option to counter zidovudine- 
